World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
57948
World Ranking
6916
National Ranking
3646

Overview

Axel Grothey is affiliated with the University of Tennessee at Knoxville in the United States. Their research primarily focuses on the field of Medicine, with a strong emphasis on Oncology.

Their work spans several subfields, including:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Pathology and Forensic Medicine
  • Cancer Research
  • Surgery

Grothey's research covers a variety of topics, particularly related to colorectal and gastric cancers as well as cancer diagnostics and treatment. Key topics include:

  • Colorectal Cancer Treatments and Studies
  • Genetic factors in colorectal cancer
  • Gastric Cancer Management and Outcomes
  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Colorectal Cancer Surgical Treatments

Frequent publication venues for Grothey's work reflect their medical and oncological expertise. Notable journals include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • UNC Libraries
  • The Oncologist
  • ESMO Open

Grothey has contributed to several recent papers, such as:

  • Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines, 2021, Annals of Oncology
  • A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group, 2020, The Oncologist
  • Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study, 2021, Journal of Clinical Oncology
  • Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial, 2021, The Lancet Oncology
  • Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials, 2020, The Lancet Oncology

Collaboration is a key aspect of Grothey's research, with frequent coauthors including:

  • Takayuki Yoshino
  • Eric Van Cutsem
  • Josep Tabernero
  • Qian Shi
  • Richard M. Goldberg

Best Publications

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Axel Grothey;Eric Van Cutsem;Alberto Sobrero;Salvatore Siena

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

    Daniel J. Sargent;Silvia Marsoni;Genevieve Monges;Stephen N. Thibodeau

  • Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data

    Anna D. Wagner;Wilfried Grothe;Johannes Haerting;Gerhard Kleber

  • Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

    Scott Kopetz;George J. Chang;Michael J. Overman;Cathy Eng

  • Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment

    Axel Grothey;Daniel Sargent;Richard M. Goldberg;Hans Joachim Schmoll

  • Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    Scott Kopetz;Axel Grothey;Rona Yaeger;Eric Van Cutsem

  • Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

    Al B. Benson;Alan P. Venook;Lynette Cederquist;Emily Chan

  • Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study

    Josep Tabernero;Takayuki Yoshino;Allen Lee Cohn;Radka Obermannova

  • NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines

    Al B Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Lynette Cederquist

  • Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

    Axel Grothey;Alberto F. Sobrero;Anthony F. Shields;Takayuki Yoshino

  • Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

    Axel Grothey;Mary M. Sugrue;David M. Purdie;Wei Dong

  • Rectal cancer, version 2.2018 clinical practice guidelines in Oncology

    Al B Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Lynette Cederquist

  • Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

    G. Folprecht;A. Grothey;S. Alberts;H.-R. Raab

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray

  • Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies

    Sherry Wolf;Debra Barton;Lisa Kottschade;Axel F Grothey

  • A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

    Humaid O. Al-Shamsi;Waleed Alhazzani;Ahmad Alhuraiji;Eric A. Coomes

  • Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel Sargent;Alberto Sobrero;Axel Grothey;Michael J. O'Connell

  • Cyclooxygenase-2: a novel target for cancer chemotherapy?

    Wolfram Dempke;Christoph Rie;Axel Grothey;Hans Joachim Schmoll

Frequent Co-Authors

Richard M. Goldberg
Richard M. Goldberg West Virginia University
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Hans-Joachim Schmoll
Hans-Joachim Schmoll Martin Luther University Halle-Wittenberg
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Thierry André
Thierry André Université Paris Cité
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA can open many doors beyond the traditional path of becoming a physician. For those seeking advanced clinical practice, consider the best dnp programs online to gain leadership roles in nursing and improve patient care outcomes.

Pharmacy is another rewarding healthcare field. Earning an online pharmacy degree prepares students for various roles in medication management, pharmacology, and patient counseling—essential work in any healthcare system.

With the growing reliance on digital health records, there is rising demand for experts in health data. A health information technology online degree will help you build skills for careers in healthcare data analysis, compliance, and information systems management.

For a faster route into the healthcare industry, look into the cheapest medical billing and coding online courses. This specialized field supports hospital administration and insurance processing, allowing you to enter the workforce quickly and play a vital supporting role in patient care delivery.

Best Scientists Citing Axel Grothey

Trending Scientists

Recently Published Articles